Ticker

Milestone supports advancement of PRF's drop-less ocular drug-delivery platform into next-stage U.S. clinical development for post-cataract pain and inflammation Milestone supports advancement of PRF's drop-less ocular drug-delivery platform into next-stage U.S. clinical development for post-cataract pain and inflammation

Evergreen Capital Management LLC lessened its stake in Invesco RAFI US 1000 ETF (NYSEARCA:PRF) by 26.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 27,653 shares of the company's stock after selling 10,157 shares during the quarter.

Invesco RAFI US 1000 ETF (NYSEARCA:PRF - Get Free Report) shares reached a new 52-week high during mid-day trading on Friday. The stock traded as high as $50.45 and last traded at $50.38, with a volume of 33528 shares trading hands. The stock had previously closed at $50.21. Invesco RAFI US 1000 ETF Stock

Recession probability indicators are flashing caution. The yield curve has spent extended periods inverted, the Conference Board's Leading Economic Index has posted consecutive monthly declines, and manufacturing PMI readings have hovered in contraction territory. Investors who wait until a recession is officially declared typically reposition after damage is already done. The seven ETFs below are... 7 Dividend ETFs…

LayerBio's OcuRing™-K program and broader ocular platform strengthen PRF's healthcare growth strategy DeepSolar advances from acquisition to early commercial deployment TEL AVIV, Israel, March 27, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd. (Nasdaq: PRFX) (“PRF” or the “Company”) today provided a business update for the year ended December 31, 2025, in conjunction with the filing of its Annual Report on Form 20-F.